Seglentis (Tramadol HCl/Celecoxib) Patent Expiration, LOE Window & CMS Spending

Seglentis (Tramadol HCl/Celecoxib) by Kowa Pharmaceut: FDA Orange Book core substance LOE 2030-04-19 (last listed 2031-06-03), 0 AB generics, $313K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorKowa Pharmaceut
FDA Application & PathwayN213426 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2030-04-19
Last Listed Patent or Exclusivity Date2031-06-03
Orange Book Patents (*PED Extensions)7 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$313K
2024 Medicare Part D Spend$274K
2024 Medicaid Spend$38K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel